Dr. Edington on the Evolving Treatment Paradigm of Melanoma

Video

In Partnership With:

Howard D. Edington, MD, discusses the evolving treatment paradigm of melanoma.

Howard D. Edington, MD, director, Cutaneous Oncology Program, Melanoma and Skin Cancer Center, Allegheny Health Network, discusses the evolving treatment paradigm of melanoma.

Medical therapy has undergone tremendous advances in melanoma in recent years, Edington says. The prognosis for stage IV disease, or advanced melanoma, used to be dismal, and now it has become manageable, Edington says.

Despite the progress in treating melanoma, areas of need remain, and the incidence of disease has continued to increase, Edington explains. Recent data suggest that by the year 2040, melanoma will be the second-most commonly diagnosed cancer, trailing only breast cancer, Edington concludes.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD
Elias Jabbour, MD